Table 1.

Clinical parameters and treatments of SLE patients.

SLE patients	SLEDAIa	Sexb	Agec	Ld	C3e	C4e	Anti-dsDNAg	RDh	CRPi	Nj	Ddk	Treatmentl
1	4	W	41	1620	93	17	−	−	0.11	4670	3.67	HCQ
2	0	W	27	1470	108	19	−	−	0.07	9870	0.75	HCQ/PN
3	0	W	65	2530	112	21	−	−	0.17	4760	4.5	HCQ/PN
4	0	W	64	2510	95	25	−	−	0.1	7130	10.5	HCQ
5	4	W	43	900	73	6	+	−	1.13	6870	8.67	HCQ/PN
6	2	M	59	2240	88	8	−	−	4.62	8240	1.08	MTX/PN/HCQ
7	0	W	56	1130	131	20	−	−	0.05	4070	2.58	NT
8	4	W	42	570	66	9	+	+	0.01	3120	8.83	AZA/PN/HCQ
9	0	W	40	750	62	12	+	−	1.16	7500	8.83	MTX/HCQ/PN
10	0	W	55	1740	110	15	−	−	0.35	8250	2.33	MMF/PN/HCQ
11	2	M	18	3420	129	11	+	+	NDf	12260	5.33	MMF/PN/HCQ
12	2	W	35	2250	91	23	−	+	0.08	6190	19.25	AZA/HCQ/PN
13	0	W	41	1150	NDf	NDf	−	−	0.7	3170	6.75	HCQ
Medianm	0		42	1620	94n	16n			0.14n	6870	5.33
	(0–3)		(37.5–57.5)	(1015–2380)	(76.8 –111.5)	(9.5– 20.8)			(0.072–1.023)	(4370–8245)	(2.5–8.8)

^aSystemic Lupus Erythematosus Disease Activity index (SLEDAI).

^bW: woman; M: man.

^cAge (years).

^dL: Lymphocytes/mL.

^eComplement C3 and C4 (low <90 and/or <10, mg/dL).

^fND: no determined.

^gSLE patients presented anti-double stranded DNA auto antibodies (31%, three women and one man).

^hRD: renal disease, (23% of SLE patients).

ⁱCRP: C-reactive protein (mg/dL).

^jN: Neutrophils/microliter.

^kDd: Disease duration, at the time of the study, in years (y).

^lHCQ: hydroxychloroquine; PN: prednisone; MTX: methotrexate; AZA: azathioprine; MMF: mycophenolate mofetil; NT: no treatment.

^mMedian (25th to 75th percentiles).

ⁿ n = 12.